Literature DB >> 21613958

Molecular profiling and prognostic relevance of circulating tumor cells in the blood of ovarian cancer patients at primary diagnosis and after platinum-based chemotherapy.

Bahriye Aktas1, Sabine Kasimir-Bauer, Martin Heubner, Rainer Kimmig, Pauline Wimberger.   

Abstract

OBJECTIVES: Disseminated tumor cells (DTCs) in the bone marrow (BM) were shown to be of prognostic significance in gynecological cancers. Bone marrow aspiration is less accepted by patients compared with blood drawing. In this pilot study, we applied the AdnaTest BreastCancer based on immunomagnetic enrichment, targeting common antigens on epithelial gynecological cancers, followed by multiplex reverse transcriptase-polymerase chain reaction for selection and detection of circulating tumor cells (CTCs) in the blood of 122 ovarian cancer patients at primary diagnosis and/or after platinum-based chemotherapy. Results were compared with detection of DTC in BM.
METHODS: Ten-milliliter blood was obtained before surgery (n=86) and/or after chemotherapy (n=70) and analyzed for CTC with the AdnaTest BreastCancer for the detection of EpCAM-, MUC-1-, and HER-2-transcripts. CA 125 was assessed in an additional single-plex reverse transcriptase-polymerase chain reaction. Bone marrow aspirates were analyzed in duplicate by immunocytochemistry using the pan-cytokeratin antibody A45-B/B3.
RESULTS: Before surgery, CTCs were detected in 19% of patients, expressing EpCAM (31%), MUC-1 (50%), HER-2 (31%), and CA 125 (50%), respectively. After chemotherapy, the overall detection rate for CTC was 27%, thereof EpCAM (68%), MUC-1 (47%), HER2 (21%), and CA 125 (37%). The overall detection rate for DTC in the BM was 35% before surgery and 31% after therapy. A comparison between DTC and CTC resulted in a concordance rate of 59% before surgery and 56% after chemotherapy. CTC positivity significantly correlated with shorter overall survival before surgery (P=0.0054) and after chemotherapy (P=0.047).
CONCLUSIONS: This methodological approach might help to identify molecular targets for specific biological therapies. Blood analysis could give additional information complimentary to that obtained by DTC.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21613958     DOI: 10.1097/IGC.0b013e318216cb91

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN: 1048-891X            Impact factor:   3.437


  39 in total

Review 1.  Gene expression profiling and DNA methylation analyses of CTCs.

Authors:  Evi S Lianidou
Journal:  Mol Oncol       Date:  2016-02-05       Impact factor: 6.603

2.  Orthogonal amplification of nanoparticles for improved diagnostic sensing.

Authors:  Vanessa M Peterson; Cesar M Castro; Hakho Lee; Ralph Weissleder
Journal:  ACS Nano       Date:  2012-03-23       Impact factor: 15.881

Review 3.  Liquid Biopsy in the Clinical Management of High-Grade Serous Epithelial Ovarian Cancer-Current Use and Future Opportunities.

Authors:  Lara Paracchini; Maurizio D'Incalci; Sergio Marchini
Journal:  Cancers (Basel)       Date:  2021-05-14       Impact factor: 6.639

4.  Gene expression profiling of single circulating tumor cells in ovarian cancer - Establishment of a multi-marker gene panel.

Authors:  Christina Blassl; Jan Dominik Kuhlmann; Alessandra Webers; Pauline Wimberger; Tanja Fehm; Hans Neubauer
Journal:  Mol Oncol       Date:  2016-04-20       Impact factor: 6.603

5.  Leukocyte-adjusted epigenome-wide association studies of blood from solid tumor patients.

Authors:  Scott M Langevin; E Andres Houseman; William P Accomando; Devin C Koestler; Brock C Christensen; Heather H Nelson; Margaret R Karagas; Carmen J Marsit; John K Wiencke; Karl T Kelsey
Journal:  Epigenetics       Date:  2014-03-26       Impact factor: 4.528

6.  Ultrasensitive clinical enumeration of rare cells ex vivo using a micro-hall detector.

Authors:  David Issadore; Jaehoon Chung; Huilin Shao; Monty Liong; Arezou A Ghazani; Cesar M Castro; Ralph Weissleder; Hakho Lee
Journal:  Sci Transl Med       Date:  2012-07-04       Impact factor: 17.956

Review 7.  Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies.

Authors:  Ben Davidson
Journal:  Virchows Arch       Date:  2018-08-25       Impact factor: 4.064

8.  Prognostic analysis of invasive circulating tumor cells (iCTCs) in epithelial ovarian cancer.

Authors:  Michael L Pearl; Qiang Zhao; Jie Yang; Huan Dong; Shaun Tulley; Qiao Zhang; Marc Golightly; Stanley Zucker; Wen-Tien Chen
Journal:  Gynecol Oncol       Date:  2014-06-24       Impact factor: 5.482

Review 9.  Circulating tumor cells as trigger to hematogenous spreads and potential biomarkers to predict the prognosis in ovarian cancer.

Authors:  Maria Luisa Gasparri; Delia Savone; Raad Aris Besharat; Ammad Ahmad Farooqi; Filippo Bellati; Ilary Ruscito; Pierluigi Benedetti Panici; Andrea Papadia
Journal:  Tumour Biol       Date:  2015-10-26

Review 10.  Circulating tumor cells: advances in isolation and analysis, and challenges for clinical applications.

Authors:  Ramdane Harouaka; Zhigang Kang; Si-Yang Zheng; Liang Cao
Journal:  Pharmacol Ther       Date:  2013-10-14       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.